Danno Pharmaceuticals is working hand-in-hand with Johnson and Johnson to develop a new drug for non-tuberculosis branch Bacillus

On January 18, Dano Pharmaceuticals announced a partnership with Johnson and Johnson's Janssen Pharmaceuticals.
according to the agreement, the latter will use the former's multi-target joint molecular new drug development platform to jointly find a new combination therapy for non-tuberculosis mycobacteria (NTM) infection.
According to the Guidelines for diagnosis and treatment of mycobacteria non-TB (2020 edition), NTM refers to Mycobacteria tuberculosis in line with groups and mycobacteria leprosy, which most often invades the lungs of the human body and has clinical manifestations similar to tuberculosis, including systemic symptoms and local damage, and has a higher incidence in patients with underlying lung disease or immune system disease.
recent years, the incidence of NTM lung disease has been increasing around the world and is rapidly becoming a serious public health problem as the environment changes, testing techniques are updated and doctors' meaning for the disease increases.
on the drug treatment of the disease, often need 3 or more anti-infective drugs for treatment, treatment cycle of more than 2 years, patient tolerance and treatment prognostic are poor.
, there are significant unsealed medical needs in the field of the disease that need to be addressed urgently.
founded in Suzhou in 2013, Danno Pharmaceuticals is a clinically innovative pharmaceutical research and development company specializing in the development of differentiated antimicrobial new drugs to address unsolved medical needs in the field of antimicrobials.
seven years since its establishment, the company has built a powerful antibacterial new drug research and development pipeline with its own multi-target joint molecular technology and background patents, and its leading product TNP-2092 injection is a multi-target joint molecule, by inhibiting The synergy of RNA polymerase, DNA rotary enzyme and topological isomerase IV to achieve biofilm sterilization activity was approved by the FDA in January 2020 for the treatment of artificial joint infections and is expected to be the world's first therapy in this field.
it is worth mentioning that TNP-2092 oral agents have also entered Phase 2 clinical trials, and received major new drug creation national science and technology major special support.
TNP-2092 is in the preclinical development phase for the treatment of diabetic foot infections and superbug infections.
TNP-2198 is another unique multi-target concedes molecule of Dano Pharmaceuticals, with multi-target synergy mechanism, strong bactericidal activity and low frequency of drug resistance to drug-resistant strains, and has a wide range of applications in the treatment of Helicobacter pyridobacteria infection, bacterial vaginosis and Thyrobacteria infection.
, TNP-2198 has entered the phase II clinical ller effect verification stage.
Bioaversing Source: Biological Exploration Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mays Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here